Dan Rock is the Chief Scientific Officer at Cartography Biosciences; he serves as the lead of scientific operations, aligning future scientific strategies with the company’s mission and vision. Prior to Cartography, he was the Vice President of Pharmacokinetics, Dynamics, Metabolism and Bioanalytics at Merck where he was responsible for the design, optimization and translation of novel biologics and small molecules into the clinic. Dan completed his PhD studying physical chemistry at Washington State University. Outside of work, Dan spends time traveling with his family and bicycling.
Recent Posts
- Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer
- Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens
- Cartography Receives FDA Investigational New Drug (IND) Approval and Fast Track Designation for Lead Program CBI-1214 for Colorectal Cancer
- Cartography Secures $67 Million Series B Financing to Advance Differentiated Oncology Pipeline of Antibody-Based Therapies into the Clinic
- Cartography Names Dirk Nagorsen, M.D., as Chief Medical Officer in Expansion of Its Clinical Team
Recent Comments
No comments to show.